{"version":"1.0","type":"link","title":"Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate.","author_name":"Chang HW 외","author_url":"https://prs-insight.online/author/Chang%20HW","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/101492","thumbnail_width":1200,"thumbnail_height":630}